DexCom, Inc. DXCM recently collaborated with Companion Medical to enable a direct exchange of CGM (Continuous Glucose Monitoring) data from InPen into both the companies’ software applications. The ...

Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target was lowered to $87.00. Mike Kratky’s rating is based on ...

Dexcom is a buy despite a recent slowdown in US sales. The upcoming launch of Stelo, a glucose monitor for non-insulin users, has a large potential market and is expected. Ex-US growth remains strong ...

Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains the same with $100.00. Discover outperforming stocks and ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong fourth-quarter 2024 performance and a series of favorable coverage decisions are ...

The Dexcom G4 receiver, which will have an "identical" form factor to the forthcoming Bluetooth version. In a call to investors days after its app won FDA approval, Dexcom CEO Kevin Sayer shared some ...

Some of Dexcom's continuous glucose monitoring receivers have been recalled due to speaker malfunctions, which can cause you to miss alerts or alarms for dangerous blood sugar levels. According to the ...

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...

Enter long short position between 74.21 (the lower band of its horizontal resistance zone) and 75.94 (the upper band of its horizontal resistance zone).Market Index Analysis DexCom (DXCM) is a member ...

DexCom, Inc. DXCM recently collaborated with Companion Medical to enable a direct exchange of CGM (Continuous Glucose Monitoring) data from InPen into both the companies’ software applications. The ...